Expert physicians and clinical researchers summarize and explain all the recent advances in the biology and treatment of bone marrow-based malignancy. On the biological side, the authors show the characteristics of the malignant cell and describe the significant roles played by oncogenic changes, chromosomal anomalies, Kaposi's sarcoma herpes virus, and cytokines. New epidemiological findings and prognostic factors are also analyzed. On the clinical side, the authors provide a comprehensive review of conventional treatment regimens, as well as a discussion of newer experimental approaches...

Maurie Markman and a panel of distinguished clinicians and leading clinical investigators comprehensively review the current status of regional antineoplastic drug delivery in the management of malignant disease. These authorities present a critical analysis of both the rationale and limitations of regional therapy and discuss potential clinical trials designed to explain the effectiveness of this method of therapy in special settings. Their presentations describe many exciting and innovative strategies for using regional drug delivery in anticancer therapy, including coverage of such areas...

Leading transplant physicians critically review and interpret twenty-one key clinical challenges in bone marrow/hematopoietic cell transplantation, and offer their best personal recommendations for treatment. Topics range from transplant strategies to complications of bone marrow transplantation, including a discussion of the indications, benefits, and the risks for a variety of leukemias, lymphomas, and solid tumors. The authors debate such contentious issues as the appropriateness of transplants in older patients, how many stem cells are sufficient for engraftment, and the pros and cons of...

Alan B. Weitberg, MD, and a panel of internationally recognized basic scientists and clinicians present a comprehensive discussion of lung cancer, including a practice-oriented review of its diagnosis, evaluation, and treatment. The contributors offer not only an understandable description of its molecular origins-an essential key to developing future therapies and preventive measures-but also rigorously discuss well-tested approaches, as well as those that are currently being evaluated for future use in both the laboratory and clinic. The book also elucidates the creation and effective...

Pui (U. of Tennessee Health Science Center) presents 42 papers that are devoted to identifying and discussing pivotal issues that might be resolved through better applications of current methods of leukemia management, rather than waiting for laboratory discoveries to drive change. Chapters look at

Michael H. Torosian, MD, and a panel of physicians and clinical researchers critically synthesize the wide variety of treatment options available to create a state-of-the-art reference for the management of breast cancer patients. Writing from a multidisciplinary perspective, these authoritative contributors review in the light of the most recent findings the major clinical aspects of breast cancer, including, epidemiology and risk factors, breast imaging, biopsy techniques, breast-conserving surgery and reconstruction, mastectomy, and the latest developments in radiation, hormonal, and...

Strategies of treatment involving therapeutic proteins, irnrnune immune cells, or cel lular protein targets are those of greatest potential for further reducing mortality from melanoma. Therapeutic proteins or cells may inhibit melanoma cell growth either by augmentation of immune cell function or by inhibition of angiogenesis. Cytokines and melanoma antigens may be used either in vivo as a vaccine to stimulate irnrnune immune cell cell function or ex vivo to stimulate or proliferate cells for infusion. Alternatively, alteration in melanoma cell growth can occur through inhibition of protein...

In Chronic Leukemias and Lymphomas: Clinical Management, a panel of recognized experts in hematological oncology describe the unique biological features of indolent hematologic neoplasms, providing powerful insight into their clinical manifestation, highlighting potential targets for novel therapies, and distinguishing these disorders from aggressive lymphoma and Hodgkin's disease. In their integrated surveys of these chronic myeloproliferative and lymphoproliferative disorders, the authors emphasize such unique entities as prolymphocytic leukemias and cutaneous lymphomas. Special emphasis is...

The rapid growth in the number of options available for the management of colorectal cancer presents the clinician with new opportunities and new complexities. An explosion of understanding in the basic science that underlies both the disease and its potential therapies has translated into remarkable technological advances that can now be applied. So many specialties and subspecialties have now been brought to bear that it is appropriate to attempt to bring the expertise from these areas together in one volume, so that practitioners in one aspect of colorectal cancer management can maintain...

Leading biostatisticians and biomedical researchers describe many of the key techniques used to solve commonly occurring data analytic problems in molecular biology, and demonstrate how these methods can be used in the development of new markers for exposure to a risk factor or for disease outcomes. Major areas of application include microarray analysis, proteomic studies, image quantitation, genetic susceptibility and association, evaluation of new biomarkers, and power analysis and sample size.